1. known active or latent mycobacterium tuberculosis infection 2. fever (\> 38 °c) or respiratory tract infection within the past 24 hours 3. current active viral or bacterial infection 4. expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination 5. participation in another interventional study within 30 days before screening and during this study 6. known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration 7. severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (hiv-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. history of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial 9. previous positive sars-cov-2 test result 10. person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

1. known active or latent mycobacterium tuberculosis infection 2. fever (\> 38 °c) or respiratory tract infection within the past 24 hours 3. current active viral or bacterial infection 4. expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination 5. participation in another interventional study within 30 days before screening and during this study 6. known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration 7. severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (hiv-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. history of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial 9. previous positive sars-cov-2 test result 10. person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

known active or latent mycobacterium tuberculosis infection fever (> 38 °c) or respiratory tract infection within the past 24 hours current active viral or bacterial infection expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination participation in another interventional study within 30 days before screening and during this study known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration severely immunocompromised subjects, including: subjects with known infection by the human immunodeficiency virus (hiv-1); subjects with solid organ transplantation; subjects with bone marrow transplantation; subjects under chemotherapy, immunotherapy, or radiotherapy; subjects with primary immunodeficiency; treatment with any anti-cytokine therapies; treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; history of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial previous positive sars-cov-2 test result person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

known active or latent mycobacterium tuberculosis infection fever (> 38 °c) or respiratory tract infection within the past 24 hours current active viral or bacterial infection expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination participation in another interventional study within 30 days before screening and during this study known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration severely immunocompromised subjects, including: subjects with known infection by the human immunodeficiency virus (hiv-1); subjects with solid organ transplantation; subjects with bone marrow transplantation; subjects under chemotherapy, immunotherapy, or radiotherapy; subjects with primary immunodeficiency; treatment with any anti-cytokine therapies; treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; history of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial previous positive sars-cov-2 test result person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

1. known active or latent mycobacterium tuberculosis infection 2. fever (> 38 °c) or respiratory tract infection within the past 24 hours 3. current active viral or bacterial infection 4. expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination 5. participation in another interventional study within 30 days before screening and during this study 6. known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration 7. severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (hiv-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. history of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial 9. previous positive sars-cov-2 test result 10. person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

1. known active or latent mycobacterium tuberculosis infection 2. fever (> 38 °c) or respiratory tract infection within the past 24 hours 3. current active viral or bacterial infection 4. expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination 5. participation in another interventional study within 30 days before screening and during this study 6. known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration 7. severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (hiv-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. history of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial 9. previous positive sars-cov-2 test result 10. person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

1. known active or latent mycobacterium tuberculosis infection 2. fever (> 38 °c) or respiratory tract infection within the past 24 hours 3. current active viral or bacterial infection 4. expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed 5. participation in another study within 30 days before screening and during this study 6. known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration 7. severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (hiv-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. active solid or non-solid malignancy or lymphoma in the past 5 years 9. previous positive sars-cov-2 test result 10. persons is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

1. known active or latent mycobacterium tuberculosis infection 2. fever (> 38 °c) or respiratory tract infection within the past 24 hours 3. current active viral or bacterial infection 4. expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed 5. participation in another study within 30 days before screening and during this study 6. known hypersensitivity or allergy to (components of) the vpm1002 vaccine or serious adverse reactions to prior bacille calmette-guérin (bcg) administration 7. severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (hiv-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. active solid or non-solid malignancy or lymphoma in the past 5 years 9. previous positive sars-cov-2 test result 10. persons is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator